Chinese medical journal
-
Chinese medical journal · Apr 2022
A broadly neutralizing human monoclonal antibody against the hemagglutinin of avian influenza virus H7N9.
The new emerging avian influenza A H7N9 virus, causing severe human infection with a mortality rate of around 41%. This study aims to provide a novel treatment option for the prevention and control of H7N9. ⋯ The mAb 6-137 could be an effective antibody as a prophylactic or therapeutic biological treatment for the H7N9 exposure or infection.